Effect of IFNβ and anti-IFNβ antibodies on NK cells in multiple sclerosis patients
P Perini, M Wadhwa, M Buttarello, A Meager… - Journal of …, 2000 - Elsevier
We analysed longitudinally the numbers of CD3–CD16+ (natural killer cells, NK) and CD3–
CD57+ cells (a subset of NK) in 15 IFNβ1b-and 12 IFNβ1a-treated relapsing–remitting
multiple sclerosis (RRMS) patients. IFNβ1b (Betaferon®)-treated RRMS patients showed a
rapid and marked reduction in the number of both NK subsets which started 1 month after
therapy initiation, and reached highest significance after 3 months (P= 0.000); however,
figures reverted to pre-treatment values following the appearance of anti-IFNβ antibodies. In …
CD57+ cells (a subset of NK) in 15 IFNβ1b-and 12 IFNβ1a-treated relapsing–remitting
multiple sclerosis (RRMS) patients. IFNβ1b (Betaferon®)-treated RRMS patients showed a
rapid and marked reduction in the number of both NK subsets which started 1 month after
therapy initiation, and reached highest significance after 3 months (P= 0.000); however,
figures reverted to pre-treatment values following the appearance of anti-IFNβ antibodies. In …